Showing 93 news articles about Changing treatment

Filters Content type: Editors' picks Topic: Changing treatment

A change of HIV treatment may be necessary because of side-effects, the development of drug resistance, treatment not being fully effective or because of interactions between HIV drugs and other medications.

Drug interactions & pharmacokinetics

Small Study Finds No Need for Double-Dosing Dolutegravir After Switching From Failing Efavirenz-Based Regimen

Editor's pick
TheBodyPro
17 April 2024
Resistance

Widely used HIV drug in South Africa flagged for reports of resistance – but experts say don’t panic

Editor's pick
Spotlight
16 April 2024
Changing treatment

Voices from Zambia: Improving HIV Treatment with DRV/r

Editor's pick
Clinton Health Access Initiative
30 November 2023
Changing treatment

One Third of French Group Has Not Changed Antiretrovirals for Over 10 Years

Editor's pick
NATAP
27 October 2023
Weight gain & lipodystrophy

Weight Loss or Gain Predictors Hard to Find in INSTI-to-PI Switch Trial

Editor's pick
NATAP
19 October 2023
Hepatitis B

Hepatitis B Reactivation Risk Low in People With HIV Following Antiretroviral Switch

Editor's pick
Contagion Live
17 October 2023
Changing treatment

Second-Line Switch to Dolutegravir Noninferior in HIV

Editor's pick
HealthDay News
26 June 2023
Injectable & long-acting HIV treatment

Study of Weekly Oral HIV Treatment Resumes

Editor's pick
POZ
8 May 2023
People with limited treatment options

Study Bite: Switching to B/F/TAF Plus Doravirine in Multidrug-Resistant PLWH

Editor's pick
TheBodyPro
5 May 2023
Injectable & long-acting HIV treatment

Clinic finds almost half of people who want long-acting HIV treatment don’t initiate it

Editor's pick
CATIE
30 March 2023
Injectable & long-acting HIV treatment

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

Editor's pick
ViiV press release
23 February 2023
Access to healthcare

Darunavir/ritonavir (DRV/r) Advocacy!

Editor's pick
AfroCAB
27 January 2023
Drug interactions & pharmacokinetics

Protease-to-Integrase Switch Greatly Reduces HIV Drug-Drug Interaction Risk

Editor's pick
TheBodyPro
25 January 2023
Injectable & long-acting HIV treatment

I Stopped Taking My HIV Pills

Editor's pick
POZ
20 January 2023
Changing treatment

A Switch to B/F/TAF Keeps HIV Suppressed, Even With Mutation

Editor's pick
Medscape (requires free registration)
20 September 2022
Side effects

Go Slow Before Switching HIV Meds Due to Metabolic Effects

Editor's pick
Infectious Disease Special Edition
14 September 2022
Changing treatment

Inflammatory Biomarkers in HIV Support Safety of Switching to 2-Drug Antiretroviral Therapy

Editor's pick
Infectious Disease Advisor
8 September 2022
Changing treatment

‘The Devil You Know’: Many People Over 50 Are Taking Outdated ART, Despite Side Effects

Editor's pick
TheBodyPro
27 April 2022
Changing treatment

Outcomes of HIV Virologic Suppression After Switching to Dolutegravir/Lamivudine

Editor's pick
Infectious Disease Advisor
28 March 2022
Weight gain & lipodystrophy

Should INSTI- or TAF-Related Weight Gain Prompt a Switch?

Editor's pick
Infectious Disease Special Edition
12 January 2022
Access to healthcare

Uganda: Shortage of raltegravir worries patients on third line HIV treatment

Editor's pick
The Independent
15 November 2021
Injectable & long-acting HIV treatment

New Guideline for Replacement ART: CAB/RPV LA Not for Everyone

Editor's pick
Medscape (requires free registration)
3 August 2021
Access to healthcare

Pricing agreement brings HIV drug darunavir within reach of LMICs

Editor's pick
Devex
29 July 2021
Access to healthcare

Innovative agreement launches affordable, optimal second-line HIV treatment in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
28 July 2021